SNW.DE लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 17:47):

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...

Stats
आज की मात्रा	2 715.00
औसत मात्रा	3 510.00
बाजार मूल्य	114.97B
EPS	€2.55 ( 2023-10-27 )
अगली कमाई की तारीख	( €1.960 ) 2024-07-25
Last Dividend	€3.56 ( 2023-05-30 )
Next Dividend	€0 ( N/A )
P/E	25.45
ATR14	€0.207 (0.23%)

Sanofi SA सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Sanofi SA वित्तीय

Annual	2023
राजस्व:	€43.07B
सकल लाभ:	€28.83B (66.95 %)
EPS:	€4.31

FY	2023
राजस्व:	€43.07B
सकल लाभ:	€28.83B (66.95 %)
EPS:	€4.31

FY	2022
राजस्व:	€45.39B
सकल लाभ:	€31.69B (69.83 %)
EPS:	€6.69

FY	2021
राजस्व:	€39.18B
सकल लाभ:	€26.92B (68.72 %)
EPS:	€4.96

Financial Reports:

No articles found.

Sanofi SA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€3.56 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Sanofi SA Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.13 - low (4.25%) | Divividend Growth Potential Score: 3.64 - Decrease likely (27.20%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€2.07	2008-05-16
Last Dividend	€3.56	2023-05-30
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	€45.47	--
Avg. Dividend % Per Year	0.00%	--
Score	1.68	--
Div. Sustainability Score	3.13
Div.Growth Potential Score	3.64
Div. Directional Score	3.38	--

Next Divdend (Est)
(2025-03-31)

€3.71 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.68

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
NXU.DE	Ex Dividend Knight	2023-05-17	Annually	0.00%
AEIN.DE	Ex Dividend Knight	2023-06-14	Annually	0.00%
GRM.DE	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
RHK.DE	Ex Dividend Junior	2023-06-09	Sporadic	0.00%
BMW.DE	Ex Dividend Junior	2023-05-12	Annually	0.00%
INS.DE	Ex Dividend Junior	2023-06-15	Annually	0.00%
SZG.DE	Ex Dividend Junior	2023-05-26	Annually	0.00%
CVS.DE	Ex Dividend Knight	2023-10-19	Quarterly	0.00%
LXS.DE	Ex Dividend Junior	2023-05-25	Annually	0.00%
2GB.DE	Ex Dividend Junior	2023-06-14	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.123	1.500	7.54	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0961	1.500	-0.0433	-0.0649	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	6.54	1.000	8.69	8.69	[3 - 30]
operatingCashFlowPerShareTTM	8.21	2.00	7.26	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.61	2.00	7.20	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.673	1.000	2.11	2.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.212	1.000	7.76	7.76	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.13

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	16.46	1.000	8.44	0	[1 - 100]
returnOnEquityTTM	0.0961	2.50	-0.0278	-0.0649	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.61	2.00	8.13	10.00	[0 - 30]
dividendYielPercentageTTM	3.82	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.21	2.00	7.26	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.619	1.500	-7.46	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.179	1.000	8.03	0	[0.1 - 0.5]
Total Score				3.64

Sanofi SA

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.